Press Releases

Press Releases

Filters
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
Viatris Wins Court Decisions on Sanofi Appeals of Lantus® Patent Invalidations
Viatris to Move its Investor Event Previously Scheduled for January 7 to no Later Than February 28 When the Company Expects to Report its Fourth Quarter 2021 Results
Viatris Named by Newsweek as One of America's Most Responsible Companies
Viatris Wins Federal Circuit Court Appeal Upholding District Court Decision Invalidating Biogen's Tecfidera® Patent
Viatris to Participate in Evercore ISI 4th Annual HealthCONx Conference
Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Viatris Donates $1 Million as Founding Champion to New Orleans-based SBP's "Got Your Back" fund in Support of Housing Solutions for Veterans in Disaster-Impacted Communities
Viatris' First-Ever Interchangeable Insulin Biosimilar Preferred on Express Scripts' Largest Formulary
Viatris Inc. to Release Third Quarter 2021 Financial Results on Nov. 8, 2021
Displaying 1 - 10 of 34